Shots:

• The study evaluates the effectiveness of the Guardant Reveal liquid biopsy test to detect MRD in patients with stage I-IV colorectal cancer after curative intent therapy
• The blood samples were taken from intent population within 1mos. after treatment completion and in the subset of patients with clinical follow-up of 1yr- all patients with detectable ctDNA recurred. Guardant Reveal test sensitivity & specificity (55.6% & 100%) respectively for this single timepoint
• The new test showed 91% sensitivity in detecting ctDNA by examining both genomic & epigenomic alterations of longitudinal surveillance samples

  Ref: Businesswire | Image: Guardant